|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Btg2 mRNA expression was lower in GH3 tumors compared to the parental line, and DAPT increased its expression levels in the tumor in parallel with the inhibition of its volume.
|
30121620 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that miR-6875-3p were elevated expressed in HCC tissues and cell lines, and negatively correlated with BTG2 expression, while positively correlated with tumor staging, size, degree of differentiation, and vascular invasion of HCC.
|
30621734 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nkx2-2as functioned as a competing endogenous RNA against miR-103 and miR-107, sequestering them and thereby derepressing their tumor suppressive targets BTG2 and LATS1 and impeding cell division and migration.
|
29229597 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Three CpG probes (cg01798157, cg06373167, cg23371584) that detected BTG2 hypermethylation in tumour tissues were associated with lower overall survival.
|
29656435 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, tumor (PC-3) targeting for [<sup>68</sup>Ga]3 and [<sup>68</sup>Ga]4 increased over time, with dynamic μPET showing clearer tumors images at later time points.
|
29432691 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall the results suggest that Tis21-gene therapy slows down MB tumor growth through inhibition of proliferation and enhancement of neural differentiation.
|
29538458 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TIS21<sup>/BTG2/PC3</sup> gene belongs to the antiproliferative gene (APRO) family and exhibits tumor suppressive activity.
|
29385670 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggested that BTG2 functioned as a bladder cancer tumor suppressor gene, and was induced by p53 and PTEN.
|
29239139 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study demonstrates that miR-25-3p promotes proliferation by targeting tumor suppressor BTG2 and may identify new diagnostic and therapeutic targets in TNBC.
|
29310680 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This suggests that BTG2 may function as a tumor suppressor by interfering with the Wnt/β‑catenin signaling pathway in skin cancer cells.
|
27510158 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously reported that tumor suppressor TIS21(/BTG2/Pc3) (TIS21) inhibits invadopodia formation by downregulating reactive oxygen species (ROS) in MDA-MB-231 cells.
|
25798836 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of BTG2 expression in p53-deficient tumors contributed to this metastatic potential by enhancing tumor growth in primary and metastatic sites.
|
26818199 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In fact PC3/Tis21 is a medulloblastoma-suppressor, as its overexpression in cerebellar precursors inhibits this tumor; PC3/Tis21 shows anti-tumor activity also in non-neural tumors.
|
25967096 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B‑cell translocation gene 2 (BTG2) is a tumor suppressor gene, which belongs to the anti‑proliferation gene family.
|
26151427 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BTG2: a rising star of tumor suppressors (review).
|
25405282 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BTG2 overexpression decreased tumor cell growth, while BTG2 knockdown illuminated the opposite effect in xenograft animal studies.
|
25721086 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Over 90% of tumor tissues revealed strong methylation at CpG islands of the BTG2 gene, compared with no methylation in the normal tissues, implying epigenetic regulation of BTG2 expression in bladder carcinogenesis.
|
25284287 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher levels of BTG2 expression in tumour cells have been linked to a better clinical outcome for several cancer entities.
|
23299537 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BTG2 is a tumor suppressor gene.It is frequently downregulated in human cancer tissues, and its loss is associated with cancer cell metastasis, suggesting that the suppression of BTG2 plays a critical role in cancer cell migration and invasion.
|
22562501 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show that downregulation of Btg2 is not sufficient but is necessary for tumor progression since the re-introduction of Btg2 in fully progressed tumors dramatically impairs their gliomagenic potential.
|
23203087 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BTG2 protein expression was lost in 32.2% (19/59) HCC tissues, and the mRNA/protein expression correlated significantly with the increasing tumor grade (P < 0.05).
|
21327578 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In B16 cells miR-21 targeted tumor suppressor (PTEN and PDCD4) and antiproliferative (BTG2) proteins.
|
21940630 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Suppression of BTG2 enhances the motility of cells in vitro and tumor growth and metastasis in vivo.
|
21339742 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In gastric cancer, BTG2 could be thought as a tumor-inhibiting gene in some distance, so the gene could be a potential target of gene therapy.
|
19728149 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BTG2 is known to act as a pan-cell cycle regulator and tumor suppressor.
|
19546886 |
2009 |